EDGAR·FLOW

Most material SEC filings — November 6, 2026

50 filings analyzed. Top movers: PRECISION BIOSCIENCES INC, ROKU, INC, Bowman Consulting Group Ltd., Vogenx, Inc., CDT Equity Inc..
8-K PRECISION BIOSCIENCES INC
Precision BioSciences priced an underwritten offering on November 5, 2026 of 10,235,077 shares at $7.75/share and 5,893,964 pre-funded warrants at $7.749995/warrant, generating ~$125M gross proceeds before fees. Underwriters: TD Securities USA LLC and Guggenheim Securities LLC. Net proceeds to fund PBGENE-HBV and PBGENE-DMD development and working capital. Closing expected November 6, 2026.
▲ Likely positive · significance 99 · 8-K Agent
8-K ROKU, INC
On November 6, 2026, Roku, Inc. merged with and into Falcon Merger Sub 2, LLC (renamed Roku, LLC), with Fox Corporation as the sole member holding 100% ownership. The merger was executed pursuant to an Agreement and Plan of Merger dated June 14, 2026. Roku transitioned from a Delaware corporation to a Delaware limited liability company wholly owned by Fox Corporation.
▼ Likely negative · significance 98 · 8-K Agent
8-K Bowman Consulting Group Ltd.
Bernhard Capital Partners completed its all-cash acquisition of Bowman Consulting Group Ltd. for approximately $1 billion on November 6, 2026. Bowman, valued at ~$408.7M market cap, becomes privately held and will delist from Nasdaq. The transaction represents a transformational exit for the engineering services firm, with Bernhard providing capital and infrastructure expertise to support organic growth and strategic acquisitions.
▲ Likely positive · significance 95 · 8-K Agent
8-K Vogenx, Inc.
Vogenx completed an $93.4M IPO in August 2026, issuing 7,187,500 shares at $13/share and netting $84.4M after underwriting costs. As of September 30, 2026, cash and marketable securities totaled $82.1M versus $601k at year-end 2025. Q3 2026 net loss was $4.9M ($0.47/share) versus $284k ($0.05/share) in Q3 2025, driven by $1.8M operating expenses and a $3.4M warrant liability mark-to-market loss.
▲ Likely positive · significance 92 · 8-K Agent
SCHEDULE 13D/A CDT Equity Inc.
Dr. Andrew Regan, through Corvus Capital Limited and Manoira Limited, holds 2,064,698 shares (22.15% of CDT Equity Inc.) and proposes acquiring all outstanding shares at $2.00/share—a 96.3% premium to the $1.018 closing price on November 4, 2026. CDT's market cap is ~$1.036M while stockholders' equity is ~$103M and Sarborg holdings valued at ~$161M, creating a significant discount-to-assets that Regan attributes to chronic dilution from at-the-market issuances and reverse splits. Corvus demands the board suspend ATM offerings, form an independent committee, and respond within 5 days.
▲ Likely positive · significance 92 · Ownership Agent
8-K BARFRESH FOOD GROUP INC.
On November 5, 2026, Barfresh Food Group Inc. received notice of failure to satisfy continued listing standards. The filing does not specify which exchange, which standard was violated, or remediation timeline. This is a critical regulatory event for a $19.8M market-cap company.
▼ Likely negative · significance 92 · 8-K Agent
8-K Fifth Era Acquisition Corp I
On November 5, 2026, Fifth Era Acquisition Corp I received a delisting notice from its exchange (Item 3.01) for failure to satisfy continued listing rules or standards. The filing provides notice of this delisting or transfer of listing but does not specify the particular rule violated, timeline for cure, or remediation plan in the extracted text.
▼ Likely negative · significance 92 · 8-K Agent
8-K CURIS INC
On November 2, 2026, Curis Inc. received notice of delisting or failure to satisfy continued listing standards. The filing indicates Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing) was triggered. No specific remediation plan, timeline, or counterparty details are provided in this 8-K filing.
▼ Likely negative · significance 92 · 8-K Agent
8-K Knightscope, Inc.
On November 4, 2026, Knightscope received notice of failure to satisfy continued listing rules or standards, triggering Item 3.01 disclosure. The filing does not specify which exchange, which listing standard was violated, or what remedial actions are available. The company's public market value is approximately $34.4M.
▼ Likely negative · significance 92 · 8-K Agent
8-K Elme Communities
Elme Communities established a liquidating trust effective October 7, 2026, pursuant to a Plan of Sale and Liquidation approved by shareholders on October 30, 2025. Initial Trustees Paul T. McDermott and W. Drew Hammond accepted trusteeship on October 7, 2026; Mark E. Chertok (FTI Consulting) will assume trusteeship after asset transfer on November 6, 2026. The trust will liquidate all company assets, wind down operations, pay liabilities, and distribute residual proceeds to shareholders (becoming 'Units' in the trust). Chertok/FTI will receive $10,000/month advisory fee plus hourly billing for additional services. All shareholders automatically receive one Unit per share held; trust duration capped at three years unless extended. Former executives receive consulting agreements (at $250–$300/hour, through April 30, 2027) and release from all prior employment claims.
▼ Likely negative · significance 88 · 8-K Agent
8-K Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals announced a private placement of up to $50.0M gross proceeds ($30.8M upfront + $19.2M from warrant exercises) with healthcare-focused institutional investors, closed August 28, 2026. Simultaneously, the company reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome: 4 of 6 patients (66.7%) achieved primary endpoint of ≥1-grade IGA improvement (p=0.0087 vs. pre-specified alpha 0.0215); key secondary endpoint also significant (p=0.0070). FDA granted Rare Pediatric Disease and Fast Track designations to QRX003 for Peeling Skin Syndrome; EMA granted Orphan Drug Designation. Company expects to complete 20-patient enrollment by end-2026 and report topline Phase 2/3 data Q2 2027.
▲ Likely positive · significance 82 · 8-K Agent
8-K Utz Brands, Inc.
On July 20, 2026, Utz Brands agreed to be acquired by subsidiaries of Intersnack Group GmbH & Co. KG for $14.25 per share in cash. Upon closing (expected Q4 2026), the Rice and Lissette Family Entities and Intersnack will each own 50% of Utz Brands Holdings, LLC. Q3 2026 saw net sales decline 2.3% to $369.2M, adjusted gross profit margin fall 530bps to 27.2%, and adjusted net income plunge 57.6% to $14.2M, driven by supply chain inflation and weaker consumer demand.
▼ Likely negative · significance 78 · 8-K Agent
8-K Aligos Therapeutics, Inc.
Aligos Therapeutics reported Q3 2026 results with cash/investments declining from $77.8M (Dec 2025) to $31.1M (Sept 2026)—a 60% burn in nine months. The company's Phase 2 B-SUPREME study of pevifoscorvir sodium enrolled 245 participants (131 HBeAg+, 114 HBeAg−) with topline data expected late Q3 2027. Cash runway extends only to Q1 2027. Net loss was $21.9M in Q3 2026 vs. $31.5M in Q3 2025; R&D expenses fell to $18.9M from $23.9M year-over-year. Partner Amoytop is funding ALG-170675 Phase 1 studies in China.
▼ Likely negative · significance 78 · 8-K Agent
8-K OneMedNet Corp
OneMedNet reported preliminary Q3 2026 revenue of approximately $1 million, representing 242% sequential growth from Q2 2026 ($0.41M implied) and 465% year-over-year growth from Q3 2025 ($0.19M implied). The company provided Q4 2026 revenue guidance of $12–14 million, pending customer acceptance. This revenue acceleration follows the company's scaling of its de-identification pipeline and delivery infrastructure during 2026.
▲ Likely positive · significance 78 · 8-K Agent
8-K FiEE, Inc.
FiEE's subsidiary FiEE Channel Limited completed a Kyoto art exhibition and auction (October 23–25, 2026) generating approximately $2.9 million in total artwork transaction value. FiEE captured approximately $1.3 million in service revenue from the event. The company plans regular art events targeting younger collectors and developing art advisory services as a recurring revenue stream.
▲ Likely positive · significance 78 · 8-K Agent
SCHEDULE 13D X Financial
Mangrove Coast Investment Limited (controlled by CEO Yue Justin Tang) submitted a preliminary non-binding proposal on November 6, 2026 to acquire X Financial in a going-private transaction at $6.03 per ADS ($1.005 per ordinary share), representing a 28.3% premium to the last closing price and 25.1% to the 30-day VWAP. Mangrove already owns 93.45% of voting power. Financing will combine equity from Mangrove/affiliates and third-party debt; due diligence and definitive agreements are to be negotiated in parallel.
— Neutral · significance 78 · Ownership Agent
4 Kodiak Sciences Inc.
Director BAKER BROS. ADVISORS LP (KOD) bought 247K shares (~$24.3M) on the open market (1.2% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
8-K REED'S, INC.
Reed's, Inc. (market cap ~$18.5M) amended its senior secured loan with Cantor Fitzgerald Securities (administrative agent) and Whitebox entities as lenders, effective November 6, 2026. The amendment requires the company to receive at least $2,500,000 in cash equity contributions by November 20, 2026, or face an event of default. It also establishes a minimum Cash/Inventory/AR Liquidity covenant of $11,000,000 and imposes a $25,000 extension fee payable to Whitebox by November 20, 2026.
▼ Likely negative · significance 78 · 8-K Agent
4 MADRIGAL PHARMACEUTICALS, INC.
Director BAKER BROS. ADVISORS LP (MDGL) bought 92K shares (~$35.0M) on the open market (4.3% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
4 KINDER MORGAN, INC.
Executive Chairman KINDER RICHARD D (KMI) bought 500K shares (~$15.0M) on the open market (0.2% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive · significance 78 · Insider Agent
8-K/A TruGolf Holdings, Inc.
On October 8, 2026, TruGolf (legal acquirer, $3.2M market cap) completed a reverse acquisition of Polymath Research Inc. (accounting acquirer). TruGolf issued 257,494 Class A shares and 136,956 Series C preferred shares (stated value $136.956M) to Polymath shareholders. Series B warrant holders exercised warrants for 3,278 Series B shares, raising $2.95M gross proceeds ($2.595M net after $355K in fees). Pro forma combined assets at June 30, 2026 were $38.5M; pro forma combined net loss for 2025 was $12.56M. Polymath's $10.79M in crypto assets remain on books at historical value.
▼ Likely negative · significance 78 · 8-K Agent
8-K Sylvamo Corp
Sylvamo entered a put option agreement with Midas Atlantic Partners (partnered with The Najafi Companies) for a binding offer to acquire Sylvamo's Europe business, including uncoated freesheet mills in Saillat, France and Nymolla, Sweden, plus forestry operations. Sylvamo will receive 20% of future distributions post-closing. Closing expected by end of Q1 2027, subject to works council consultation.
— Neutral · significance 72 · 8-K Agent
8-K TERAWULF INC.
TeraWulf announced Q3 2026 results with HPC lease revenue of $63.0M (83% of $76.2M total revenue) and executed a transformational 20-year lease with Anthropic for 401 MW at Justified Data Campus representing ~$19B contracted revenue. Google provided credit backstop; Fluor signed EPC agreement. Lake Mariner: 102 MW operational with 336 MW (CB-4, CB-5) under construction progressing within cost guidance ($8–10M/MW). Muskie expanded to 1 GW contracted power via October amended agreements (subject to regulatory approval). Abernathy JV monetization closed at ~$530M aggregate consideration (~20% IRR); company ended Q3 with $2.4B cash and upsized revolving credit from $250M to $400M (+$150M accordion).
▲ Likely positive · significance 72 · 8-K Agent
8-K FLUOR CORP
Fluor reported Q3 2026 revenue of $3.7B (up 10% YoY), adjusted EPS of $0.77 (up 13%), and record new awards of $10.9B including $7.5B for LNG Canada Phase 2 plus two mining projects. Backlog grew 21% to $34.3B (69% reimbursable). The company repurchased $300M in shares (Q3) and $1.1B year-to-date toward a $1.4B target. Management affirmed 2026 adjusted EBITDA guidance of $500–$525M despite a slight decline in adjusted EBITDA margin (3.8% vs 4.8% prior year).
▲ Likely positive · significance 72 · 8-K Agent
8-K Sylvamo Corp
Sylvamo agreed to a put option with Midas Atlantic Partners and The Najafi Companies for a binding offer to sell its Europe business, comprising uncoated freesheet mills in Saillat (France) and Nymolla (Sweden), plus forestry operations. The company recorded a $342M pre-tax impairment charge on the Europe segment in Q3 2026 and reclassified it as discontinued operations; Q3 continuing operations generated $645M sales and $85M net income ($2.13/diluted share), while Europe contributed $178M sales and a $284M loss. After closing, Sylvamo will focus on Latin America and North America with ~$6–7M quarterly increase in corporate costs.
▼ Likely negative · significance 72 · 8-K Agent
8-K PPL Corp
PPL reported Q3 2026 ongoing EPS of $0.54 vs. $0.48 YoY; narrowed full-year 2026 forecast to $1.92–$1.96 per share (midpoint $1.94). Increased long-term annual EPS growth target from 6–8% to 7–9% through 2030. Announced $25B capital plan for 2027–2030 (vs. prior $23B for 2026–2029), driving 10% average annual rate base growth. Invitium Energy agreed to 2 GW generation supply to QTS for Pennsylvania data center (20-year term, nonbinding term sheet). Provided 2027 forecast of $2.06–$2.14 per share (midpoint $2.10, 8.2% growth vs. 2026). Identified $12–16B additional generation investment opportunity through 2032 that could drive 9%+ CAGR from 2026–2030.
▲ Likely positive · significance 72 · 8-K Agent
8-K Acrivon Therapeutics, Inc.
Acrivon acquired ACR-525 (a Phase 2-ready oral JAK1 inhibitor) and a PKC-theta inhibitor preclinical program from Aqilion AB for undisclosed cash consideration with no royalties or milestones. The deal establishes immunology and inflammation as a strategic pillar alongside oncology; ACR-525 targets eosinophilic esophagitis first, with potential in IBD and autoimmune diseases. Concurrently, Acrivon terminated all future royalty and milestone obligations between Aqilion and LEO Pharma on ACR-525.
▲ Likely positive · significance 72 · 8-K Agent
8-K Strive, Inc.
Strive completed a registered public offering of 7,000,000 shares of 15% Series A Perpetual Preferred Stock (SATS) on October 20, 2026, raising net proceeds of approximately $609.0 million. Year-to-date through September 30, 2026, the company acquired 20,373 bitcoin and an additional 15,124 bitcoin October 1–30, 2026. As of October 30, 2026, Strive held $490.4 million in cash and equivalents, $50.1 million in STRC preferred stock holdings, and digital assets (primarily bitcoin) valued at $2.34 billion (Q3 2026 balance sheet), with 118.1 million Class A shares and 14.0 million SATA preferred shares outstanding.
▲ Likely positive · significance 72 · 8-K Agent
10-Q Aligos Therapeutics, Inc.
Aligos Therapeutics extended its lease at One Corporate Drive, South San Francisco (38,675 sq ft, entire 2nd floor) from expiring March 31, 2027 to March 31, 2034 (84 months). Base rent escalates from $2.16M annually (year 1) to $2.65M (year 7); tenant receives 10 months of base rent abatement plus $773,500 refurbishment allowance ($20/sq ft). Counterparty: Britannia Biotech Gateway Limited Partnership (landlord). Tenant gains ROFR on 1st floor space and ROFO on adjacent building 2 Corp Drive, plus early termination option at March 31, 2031 for $2.48M.
— Neutral · significance 72 · Periodic Agent
SCHEDULE 13D/A BlackRock TCP Capital Corp.
Between October 14 and November 5, 2026, Saba Capital Management purchased approximately 1,602,977 common shares of BlackRock TCP Capital Corp. in open-market transactions at prices ranging from $3.96 to $4.37 per share. Total investment approximately $6.6M. The largest single purchase was 698,126 shares on 11/5/2026 at $4.10/share. This represents a meaningful accumulation by an activist investor.
— Neutral · significance 72 · Ownership Agent
8-K DATA I/O CORP
Data I/O announced the appointment of Douglas Adams as SVP Global Services, Support and Quality on November 3, 2026. Adams rejoins CEO Bill Wentworth and VP Monty Reagan—executives who previously built Source Electronics into the world's largest independent programming services business. The appointment follows Data I/O's October 21, 2026 acquisition of V-TEK, Inc. and A J Programming, Inc., which is anticipated to double the Company's revenue and expand it into data centers, AI, photonics, industrial automation, medical, aerospace/defense markets. A J Programming will operate as a subsidiary while Data I/O pursues Programming-as-a-Service (PaaS) expansion.
▲ Likely positive · significance 72 · 8-K Agent
8-K PINNACLE WEST CAPITAL CORP
Pinnacle West's Arizona Public Service subsidiary increased long-term weather-normalized retail sales growth guidance from 4%-6% to 8%-10% through 2030, driven by 5.8 GW of committed load (primarily data centers, semiconductors, manufacturing). Total APS capital expenditures for 2025-2028 are estimated at $10.35B; transmission capex alone projects $6B+ through 2035. The company filed a 2025 rate case requesting $609M net revenue increase (14.69% customer bill impact) and proposes a Formula Rate Adjustment Mechanism for future annual updates.
▲ Likely positive · significance 72 · 8-K Agent
10-Q IGC Pharma, Inc.
On June 30, 2026, IGC Pharma converted two outstanding loans into restricted common stock: Claudia Grimaldi's $281,203 loan converted to 1,041,493 shares, and Ram Mukunda's $286,540 loan converted to 1,061,260 shares, both at $0.27/share (the closing price that day). The shares are restricted securities bearing customary restrictive legends and cannot be sold without registration or exemption. Notably, both Grimaldi and Mukunda hold officer positions (VP/CFO and CEO, respectively) and signed the October 2026 clarification letters and Sarbanes-Oxley certifications.
▼ Likely negative · significance 72 · Periodic Agent
8-K Janus Living, Inc.
Janus Living, Inc. executed an underwriting agreement on November 4, 2026, to sell 26,250,000 shares of Class A-1 Common Stock at $28.50 per share (~$749M gross proceeds) to a syndicate led by BofA Securities, J.P. Morgan Securities, Wells Fargo Securities, and Goldman Sachs. An additional 3,937,500 shares (~$112M) are subject to a 30-day overallotment option. The company is a REIT externally managed by Healthpeak Investment Management. Underwriting discount is $1.06875 per share (~3.75%).
▲ Likely positive · significance 72 · 8-K Agent
8-K Entera Bio Ltd.
Entera completed a $275M private placement in July 2026 led by BVF Partners with participation from Longitude Capital, Vivo Capital, and others, bringing cash to $265.9M as of Q3 2026. The company expects to activate the first EB613 Phase 3 site in late 2026, enrolling ~900 postmenopausal women (600 EB613, 300 placebo), with topline results anticipated H2 2028. Four senior clinical executives were appointed (Chief Medical Officer, SVP Medical Affairs, VP Early Development, VP Clinical Development) and two board directors added effective December 1, 2026.
▲ Likely positive · significance 72 · 8-K Agent
8-K Zenas BioPharma, Inc.
Zenas BioPharma registered a $200 million at-the-market (ATM) offering of common stock via an Open Market Sale Agreement with Jefferies LLC, dated October 8, 2025. The Registration Statement on Form S-3ASR became effective October 8, 2025; this supplemental legal opinion was delivered November 6, 2026, accompanying the prospectus supplement filing under Rule 424. The offering allows the company to sell up to $200M of shares opportunistically at prevailing market prices.
— Neutral · significance 72 · 8-K Agent
8-K Star Holdings
Star Holdings reported Q3 2026 net loss of $45.1M ($3.74 EPS loss) driven by a $53.1M non-cash mark-to-market loss on ~13.5M shares of Safehold Inc. (SAFE). The company sold municipal debt for $50.2M (realizing $4.5M gain), sold Coney Island land for $20.0M (realizing $4.7M gain), and reduced margin debt from $94.5M to $46.5M.
▼ Likely negative · significance 72 · 8-K Agent
8-K DTE ENERGY CO
DTE Energy agreed to sell substantially all DTE Vantage assets to institutional investors advised by J.P. Morgan Asset Management for approximately $3 billion, with closing expected in H1 2027. Proceeds will fund a $44.2 billion utility capital plan (2027-2031, up 30% from prior plan) focused on data center infrastructure, renewables (15 GW), and distribution hardening. New long-term operating EPS growth target: >9% CAGR from 2027–2031 baseline of $7.59–$7.73, well over 9% in 2028–2029 (vs. prior 6%–8% target). Specific contracts: 1.4 GW Oracle (approved, ramping 2027) and 1.0 GW Google (approved, ramping 2028); 5–6 GW additional pipeline. Dividend increase 7% in 2027.
▲ Likely positive · significance 72 · 8-K Agent
8-K SILGAN HOLDINGS INC
Silgan Holdings secured lender consent dated November 6, 2026, to designate its new subsidiary MetalCo as an Unrestricted Subsidiary under its credit agreement. Silgan will contribute its metal container business and metal/plastic closures business to MetalCo, which will then acquire Trivium Packaging in a joint venture with an American Industrial Partners affiliated fund. The consent also allows Silgan to use proceeds from the transaction to redeem Senior Notes rather than prepay loans, and permits limited conditionality testing for the transaction.
— Neutral · significance 72 · 8-K Agent
8-K Health In Tech, Inc.
On November 2, 2026, Health In Tech, Inc. entered into a material definitive agreement (Item 1.01) and created a direct financial obligation or off-balance sheet arrangement (Item 2.03). The 8-K filing does not disclose the counterparty name, dollar amounts, terms, or specific nature of the agreement in the accessible text provided—only that Items 1.01 and 2.03 were triggered, indicating a deal and debt/obligation occurred.
— Neutral · significance 72 · 8-K Agent
8-K NorthWestern Energy Group, Inc.
NorthWestern Energy (market cap ~$3.1B) is proceeding with its merger with Black Hills Corporation. Key milestones: Nebraska and South Dakota regulatory approvals received (May and June 2026); Montana hearing concluded May 2026 with final order expected November 12, 2026; FERC approval received May 29, 2026; shareholder approvals received April 2, 2026; Hart-Scott-Rodino antitrust waiting period expired April 20, 2026. Combined company targets ~$12B rate base with 5–7% EPS growth (vs. standalone 4–6%). NorthWestern affirms 2026 Non-GAAP EPS guidance of $3.68–$3.83 per share and maintains long-term 4–6% EPS and rate-base growth. Company forecasts $3.21B capital investment over 2026–2030.
▲ Likely positive · significance 72 · 8-K Agent
8-K AST SpaceMobile, Inc.
AST SpaceMobile announced it will build its own reusable 20-ton rocket called Blacklift, using Miranda and Vira engines from Firefly Aerospace. The deal includes: $400M cash + 10–14M ASTS shares (~$400M at forward VWAP) upfront for a perpetual manufacturing license; $250M for engines on first three launches; $250M over three years for engineering services. Total commitment: ~$1.3B. Blacklift operations begin late 2028; company will continue using external launch providers for 100+ BlueBird satellites through 2027–2028.
▲ Likely positive · significance 72 · 8-K Agent
8-K Kontoor Brands, Inc.
Kontoor Brands completed the sale of its Lee® business to Authentic Brands Group (via ABG-Storm LLC) on November 2, 2026, for an unadjusted purchase price of $750.0 million in cash, receiving approximately $698.2 million after adjustments for cash, indebtedness, and net working capital. The company is eligible for contingent earnout payments up to $250.0 million over five years (fair value estimated at $77.0 million). Kontoor plans to deploy proceeds: debt repayment to satisfy Senior Notes covenants (mandatory within 540 days), $400 million in ASR share repurchases, and $50 million in open market buybacks, leaving the company more focused on Wrangler and Helly Hansen brands.
▲ Likely positive · significance 72 · 8-K Agent
8-K Sidus Space Inc.
Sidus Space filed an 8-K on 2026-11-06 reporting non-reliance on previously issued financial statements or audit reports (Item 4.02). No specific dollar amounts, restatement details, accounting errors, or remediation steps are disclosed in the filing header or document index provided. The company has not published the substantive 8-K content detailing the nature, scope, or financial impact of the restatement.
▼ Likely negative · significance 72 · 8-K Agent
8-K TEN Holdings, Inc.
TEN Holdings reported Q3 2026 revenue of $640,000 (up 17.9% YoY to $640K from $543K), but posted a net loss of $3.734 million (down from $1.987M loss in Q3 2025), primarily due to a $1.8 million write-off of capitalized service contracts and ~$0.5 million in legal expenses. The company reduced related-party debt from $4.6M (year-start) to $0.1M, decreased total liabilities 74% to $2.0M, and raised $7.5M via a June common stock offering. Cash position improved to $3.5M (from $1.6M year-end 2025). Shares outstanding increased to 11.999M (from 2.36M prior year, post-1-for-15 reverse split). The company launched its new TEN Digital Experience Platform and appointed Ian M. Lawson as Interim CFO on September 30, 2026.
▼ Likely negative · significance 72 · 8-K Agent
8-K Pono Capital Four, Inc.
Pono Capital Four amended its merger agreement with Blackstar Orbital Technologies (dated August 5, 2026) effective November 5, 2026. The Base Purchase Price is fixed at $200 million with no debt adjustments. The Equity Plan Reserve increased from 6.0M to 7.4M Parent shares. The Company Outside Closing Date extended from an earlier date to June 30, 2027. No other material terms were modified.
— Neutral · significance 72 · 8-K Agent
8-K Datavault AI Inc.
Effective immediately (Nov 6, 2026), Datavault AI removed CEO Nathaniel Bradley (who remains on Board) and appointed Brett Moyer as new CEO/President. Simultaneously, the Board appointed Kimberly Briskey as Chair, Teri Gallo as COO, Stanley Mbugua as CFO, Sri Peruvemba as Vice Chair, and Christopher Hardt as Audit Committee Chair. Sonia Choi is no longer with the company. No financial terms, severance, or compensation details disclosed.
— Neutral · significance 72 · 8-K Agent
8-K Silo Pharma, Inc.
Silo Pharma (market cap ~$5.3M) executed a private placement on November 5, 2026, selling up to $1.1 million aggregate of common shares and pre-funded warrants to accredited investors at $1.50 per share (warrant exercise price $0.0001). The offering includes registration rights and a waiver from H.C. Wainwright. Proceeds are for working capital; use restricted from debt repayment, redemptions, litigation settlement, and FCPA/OFAC violations.
▲ Likely positive · significance 71 · 8-K Agent
8-K Delek US Holdings, Inc.
Delek US reported Q3 2026 net income of $1,133.8M ($18.22/share) and adjusted EBITDA of $1,280.4M, driven by 191% higher crack spreads and $334.7M RVO benefit from EPA small refinery exemptions. On September 29, 2026, the company issued $460M 0% convertible notes due 2031 with capped call hedges. DK repurchased $50M stock in Q3 and plans $100M more in Q4, while committing to repay the $850M term loan by quarter-end. DKL raised $230M (4.6M units at $50/unit) in August 2026. FY2026 EOP guidance raised to $250M+ cash flow improvements.
▲ Likely positive · significance 68 · 8-K Agent
8-K Airsculpt Technologies, Inc.
AirSculpt reported Q3 2026 revenue of $31.9M (down 8.7% YoY) and case volume down 9.6% same-store sales. The company reduced full-year 2026 revenue guidance to $144–146M (from $151–157M) and Adjusted EBITDA to $9–10M (from $12–14M). On November 5, 2026, the company refinanced its term loan with Blue Torch Finance LLC: $39.0M senior secured term loan plus $5.0M revolving facility, maturing November 5, 2031, replacing prior debt and extending maturity by ~5 years.
▼ Likely negative · significance 68 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.